Rapid Autopsy Protocol for Patients with Small Cell Lung Cancer
Study on Rapid Autopsy Program for Small Cell Lung Cancer
Shadia Jalal, MD
Primary Investigator
Brief description of study
Detailed description of study
Tumor tissue collected will be used for protein and gene analysis and RNA, whole exome sequencing in addition to the establishment of SCLC.
- This research is part of a discovery project in which biological and molecular markers of SCLC will be identified.
- Researchers will utilize tissue obtained from rapid autopsies to generate novel patient derived xenograft models and tumor cell lines, in addition to RNA, whole exome and whole genome sequencing, protein extraction to better understand the complex biology of SCLC and set up an infrastructure to develop relevant clinical models that will allow the development of better therapies.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Small Cell Lung Cancer, SCLC
-
Age: 18 years or above
-
Gender: All
Inclusion Criteria:
- ≥ 18 years old at the time of informed consent
- Written informed consent and HIPAA authorization for release of personal health information.
- Active SCLC diagnosis.
The purpose of this study is to investigate a rapid autopsy program for patients with Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center. Small Cell Lung Cancer is a type of lung cancer characterized by fast-growing tumors. This study will involve collecting tumor tissue from patients who have passed away with an active SCLC diagnosis to better understand the disease.
The study will use the collected tumor tissue for various analyses, including protein and gene analysis, RNA sequencing, and whole exome sequencing. The study aims to identify biological and molecular markers of SCLC, generate patient-derived models, and set up an infrastructure to develop better therapies for SCLC.
- Who can participate: Adults aged 18 years or older with an active diagnosis of Small Cell Lung Cancer can participate. Participants must provide written informed consent and HIPAA authorization.
- Study details: Participants will be involved in a rapid autopsy program where tumor tissue is collected after passing. This tissue will be used for research purposes, including sequencing and protein analysis.